| 000 | 01578 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517153102.0 | ||
| 264 | 0 | _c20180510 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1346-8138 | ||
| 024 | 7 |
_a10.1111/1346-8138.13860 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHonda, Hiromi | |
| 245 | 0 | 0 |
_aSwitching of biologics in psoriasis: Reasons and results. _h[electronic resource] |
| 260 |
_bThe Journal of dermatology _cSep 2017 |
||
| 300 |
_a1015-1019 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdalimumab _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBiological Products _xtherapeutic use |
| 650 | 0 | 4 |
_aDermatologic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aDrug Substitution _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfliximab _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUstekinumab _xtherapeutic use |
| 700 | 1 | _aUmezawa, Yoshinori | |
| 700 | 1 | _aKikuchi, Sota | |
| 700 | 1 | _aYanaba, Koichi | |
| 700 | 1 | _aFukuchi, Osamu | |
| 700 | 1 | _aIto, Toshihiro | |
| 700 | 1 | _aNobeyama, Yoshimasa | |
| 700 | 1 | _aAsahina, Akihiko | |
| 700 | 1 | _aNakagawa, Hidemi | |
| 773 | 0 |
_tThe Journal of dermatology _gvol. 44 _gno. 9 _gp. 1015-1019 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/1346-8138.13860 _zAvailable from publisher's website |
| 999 |
_c27157768 _d27157768 |
||